Clinical Trial

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-12-23; most recent amendment 2026-06-10.
Status change: Not Yet Recruiting → Recruiting 2023-03-08
Trial Details
NCT Number NCT05666960
Lead Sponsor Rise Therapeutics LLC
Collaborators: Mayo Clinic, University of Colorado, Denver
Conditions Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Enrollment 36 participants
Start Date 2023-02-27
Primary Completion 2026-07 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-12